Inscripta has now accumulated more than $259m altogether from investors including Institut Mérieux, and will use the capital to further expand its genome engineering platform.
Inscripta, a US-based genome engineering platform developer backed by medical technology holding company Institut Mérieux, collected $125m yesterday in a series D round led by venture capital firm Paladin Capital Group.
Investment firm JS Capital Management and growth equity fund Oak HC/FT also took part in the round, along with unnamed existing shareholders.
Founded in 2015 as Muse Biotechnology, Inscripta has built a fully automated gene editing platform dubbed Onyx Digital Genome Engineering, which enables researchers to build libraries of…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
